Difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual‐center study

BACKGROUND: An accurate evaluation of neoadjuvant treatment is important to maximize the prognostic benefit of this strategy in each individual patient. The main aim of the present study is to investigate the difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron em...

Descripción completa

Detalles Bibliográficos
Autores principales: Akita, Hirofumi, Takahashi, Hidenori, Eguchi, Hidetoshi, Asukai, Kei, Hasegawa, Shinichiro, Wada, Hiroshi, Iwagami, Yoshifumi, Yamada, Daisaku, Tomimaru, Yoshito, Noda, Takehiro, Gotoh, Kunihito, Kobayashi, Shogo, Doki, Yuichiro, Sakon, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164457/
https://www.ncbi.nlm.nih.gov/pubmed/34095729
http://dx.doi.org/10.1002/ags3.12418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164457/
https://www.ncbi.nlm.nih.gov/pubmed/34095729
http://dx.doi.org/10.1002/ags3.12418

Ejemplares similares